The International Advisory Committee on Clinical Trials in Multiple Sclerosis is recommending that the clinical course descriptions of MS – relapsing-remitting (RRMS), secondary-progressive (SPMS) and primary-progressive (PPMS) – be discarded in favour of a more biology-based approach (Kuhlmann et al. Lancet Neurol 2022; epublished November 18, 2022). Read More
Latest News
MS Awards 2022 – Oddities and Observations
December 9, 2022MS Prodromedary Prize
A study in Saudi Arabia found that the most important risk factor for the development of MS was consumption of camel milk (odds ratio 2.50) (Alkhawajah et al. Neuroepidemiology 2022;56:97-103). Read More
Effectiveness of COVID boosters in MS: an update
November 30, 2022Two recent studies have reported that COVID boosters can increase the humoral response in MS patients during treatment with ocrelizumab or fingolimod. A number of studies have reported that these disease-modifying therapies (DMT) are associated with a blunted humoral response to COVID vaccination (Achiron et al. Ther Adv Neurol Disord 2021;14:17562864211012835. Gallo et al. Neurol Sci 2021;42:3523-3526). Read More
2022 – the year in review
November 29, 2022Take the survey: Looking back on 2022
In 2022, the most noteworthy event was the announcement that the COVID-19 pandemic was over. That was reassuring news, although there have been 316 million reported cases this year, about 50% of all COVID cases to date. Canada saw an average of 48 COVID-related deaths per day post-pandemic. Read More